Sites Menu > Autoimmune Diseases - Other

Autoimmune Diseases - Other

What is the evaluation and treatment strategy for Raynaud's phenomenon?

Journal of Family Practice, June, 2005 by Heather Tagliarino, Michael Purdon, Barbara Jamieson

American Behcets Disease Association

The American Behcet's Foundation was founded by a parent of a child with Behcet's Disease in 1978 in Orange County, California. In 1986, the Organization changed its name to The American Behcet's Association (ABA) and was moved to Rochester, Minnesota. Recently the name was changed to the American Behcet's Disease Association (ABDA) to clarify the nature of the organization. In 1987, the American Behcet's Association was incorporated as a nonprofit organization in the state of Minnesota and in 1989, was granted 501(c)3 tax exempt status by the Internal Revenue Service. In 1988, a medical advisory board was formed of Behcet's experts from around the country.

Myasthenia Gravis

Myasthenia Gravis Association

Ocular Manifestations of Behcet's Disease

Indian Pediatrics 2005; 42:942-945

Bechet's Disease

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)


Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis

Arthritis Research & Therapy 2006, 8:R31 doi:10.1186/ar1882 Published 10 January 2006 This study shows that the concentration of serum biomarkers of cartilage collagen breakdown and proteoglycan turnover, but not of collagen synthesis, are related to joint destruction in RA. The use of these biomarkers may be of value when studying progression of joint damage in patients with RA.

The Sjogren's Syndrome Foundation About Sjogren's Syndrome FAQs About Sjogren's Syndrome

Raynaud Phenomenon

AJN, American Journal of Nursing August 2005 Volume 105 Number 8 Pages 56 - 65

Top 10 Needs of People With Multiple Sclerosis and Their Significant Others

J Neurosci Nurs. 2006;38(5):369-373. ©2006 American Association of Neuroscience Nurses. The purpose of this study was to identify the needs of patients with multiple sclerosis (MS) and their significant others. A quantitative questionnaire, developed from focus groups and consisting of 75 needs statements, was administered to 353 MS patients and 240 significant others. Analysis produced rankings of the 10 most important needs of both groups. Rankings by the MS patients and significant others were similar. Three themes emerged. Psychosocial and other personal needs (relationship with physicians, the MS healthcare team, family, and friends) were ranked with high frequency. Information needs (information regarding MS or available support) and financial security were also ranked as important. The data validate the importance of interdisciplinary care for the MS population. Registration Required

Vasculitis and Thrombophlebitis

Last Updated: March 30, 2006. Vasculitis is a descriptive term associated with a heterogeneous group of diseases that results in inflammation of blood vessels. Arteries and veins of any size in any organ may be affected, leading to ischemic damage to organs. The pattern of vessel involvement is highly variable, leading to innumerable clinical presentations. The most common vasculitides of childhood are Henoch-Schönlein purpura and Kawasaki disease. See articles on Kawasaki Disease, Infantile Polyarteritis Nodosa, Polyarteritis Nodosa, and Takayasu Arteritis.

Connective Tissue Diseases: The Big Three

Discusses Lupus, Sjogren's and Antiphospholipid Antibody (Hughes) Syndrome.

Husbands and Wives Living With Multiple Sclerosis

Abstract Abstract: Multiple sclerosis (MS) frequently is diagnosed in young adults. Coping with symptoms of MS is challenging not only for the person with the disease, but also for his or her spouse. The well spouse often assumes the caregiving role. The purpose of this qualitative research was to investigate the experiences of persons whose spouses have MS. Twelve people participated in a 2-hour focus group: 8 men and 4 women. The husbands were, on average, 50 years old, and the wives averaged 55 years old. The length of time since diagnosis ranged from 2 to 11 years for the husbands and from 3 to 13 years for the wives. The focus group discussions were audiotaped and transcribed verbatim. Participants talked freely. Four major themes emerged: caregiver roles, need for information, relationship changes, and barriers. Men attempted to protect their wives' energy, intervening for them. Wives encouraged independence in their husbands. Spouses need information about MS, complementary interventions, and support. They want increased public awareness of invisible symptoms and awareness in the workplace of continuing capabilities of persons with MS. Role reversals were challenging for the women who felt that "MS is the third person in a marriage." Spouses need help to maintain appropriate boundaries. Limitations of the study include the small, economically homogeneous sample and the single encounter with the subjects. A longitudinal intervention study is needed. Registration Required.

Adults And Primary Immune Deficiency Diseases


Also called: Angiitis, Arteritis

No evidence for an association between the -871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjogren's syndrome

Arthritis Research & Therapy 2006, 8:R30 doi:10.1186/ar1884 Published 9 January 2006 Polyclonal B cell activation might be related to pathogenic over-expression of B-cell-activating factor (BAFF) in primary Sjögren's syndrome (pSS) and other autoimmune diseases. We therefore investigated whether BAFF over-expression in pSS could be a primary, genetically determined event that leads to the disease. The complete BAFF gene was sequenced in Caucasian pSS patients and control individuals. The only single nucleotide polymorphism frequently observed, namely -871 T/C in the promoter region, was then genotyped in 162 French patients with pSS and 90 French control individuals. No significant differences in allele (T allele frequency: 49.7% in patients with pSS versus 50% in controls; P = 0.94) and genotype frequencies of BAFF polymorphism were detected between pSS patients and control individuals. BAFF gene polymorphism was not associated with a specific pattern of antibody secretion either. T allele carriers had significantly increased BAFF protein serum levels (mean values of 8.6 and 5.7 ng/ml in patients with TT and TC genotypes, respectively, versus 3.3 ng/ml in patients with CC genotype; P = 0.01), although no correlation was observed between BAFF polymorphism and mRNA level. In conclusion, BAFF gene polymorphism is neither involved in genetic predisposition to pSS nor associated with a specific pattern of antibody production.

Plasmapheresis and Autoimmune Disease

Plasmapheresis is a process in which the fluid part of the blood, called plasma, is removed from blood cells by a device known as a cell separator. The separator works either by spinning the blood at high speed to separate the cells from the fluid or by passing the blood through a membrane with pores so small that only the fluid part of the blood can pass through. The cells are returned to the person undergoing treatment, while the plasma, which contains the antibodies, is discarded and replaced with other fluids. Medication to keep the blood from clotting (an anticoagulant) is given through a vein during the procedure.

Sneddon's syndrome: additional neurological feature in antiphospholipid (Hughes') syndrome

Postgraduate Medical Journal 2003;79:550 © 2003 Fellowship of Postgraduate Medicine

Sjogren's Syndrome

US Pharm. 2007;32(3):72-81. The most important concept to realize when selecting appropriate treatment for a patient with Sjögren's syndrome is that therapy must be adapted to the individual patient's needs and responses. Each patient will present with some similar symptoms but also with a unique set of symptoms and complaints. Pharmacists can have an active role in helping patients manage this syndrome. Providing excellent pharmaceutical care and continuity of care is the first step. Counseling and teaching patients about the syndrome as well as providing tips for improving patients' quality of life can have a dramatic impact.

Multiple Sclerosis Health Center

Multiple sclerosis affects 2.5 million people worldwide, including 400,000 Americans. Get in-depth information here on multiple sclerosis symptoms and treatments. Plus, find daily help in our online support group.

Cardiac syndrome X: a critical overview and future perspectives

Published Online First: 6 January 2006. doi:10.1136/hrt.2005.067330. Heart 2007;93:159-166. ABSTRACT: The classic definition of cardiac syndrome X (CSX) seems inadequate both for clinical and research purposes and should be replaced with one aimed at including a sufficiently homogeneous group of patients with the common plausible pathophysiological mechanism of coronary microvascular dysfunction. More specifically, CSX should be defined as a form of stable effort angina, which, according to careful diagnostic investigation, can reasonably be attributed to abnormalities in the coronary microvascular circulation.

Cell therapy for autoimmune diseases

Arthritis Research & Therapy 2007, 9:206. Cell therapy, pioneered for the treatment of malignancies in the form of bone marrow transplantation, has subsequently been tested and successfully employed in autoimmune diseases. Autologous haemopoietic stem cell transplantation (HSCT) has become a curative option for conditions with very poor prognosis such as severe forms of scleroderma, multiple sclerosis, and lupus, in which targeted therapies have little or no effect. The refinement of the conditioning regimens has virtually eliminated transplant-related mortality, thus making HSCT a relatively safe choice. Although HSCT remains a nonspecific approach, the knowledge gained in this field has led to the identification of new avenues. In fact, it has become evident that the therapeutic efficacy of HSCT cannot merely be the consequence of a high-dose immuno-suppression, but rather the result of a resetting of the abnormal immune regulation underlying autoimmune conditions. The identification of professional and nonprofessional immunosuppressive cells and their biological properties is generating a huge interest for their clinical exploitation. Regulatory T cells, found abnormal in several autoimmune diseases, have been proposed as central to achieve long-term remissions. Mesenchymal stem cells of bone marrow origin have more recently been shown not only to be able to differentiate into multiple tissues, but also to exert a potent antiproliferative effect that results in the inhibition of immune responses and prolonged survival of haemopoietic stem cells. All of these potential resources clearly need to be investigated at the preclinical level but support a great deal of enthusiasm for cell therapy of autoimmune diseases.

Scleroderma Foundation - Home Page

Atherosclerosis in Patients With Autoimmune Disorders

Arterioscler Thromb Vasc Biol. 2005 Jun 23

The Common Thread

Noel R. Rose, M.D., Ph.D., Chair, AARDA National Scientific Advisory Board, Professor of Molecular Microbiology and Immunology and Pathology The Johns Hopkins University The topic that Mrs. Ladd has asked me to discuss with you this afternoon is "Autoimmune Diseases: How Are They Related?" It is a very good topic because it forced me to think about the question.

Search our Sites


[1] [2] [3] Next

AUTOMATE your Links Pages with!



The APS Foundation of America, Inc. website and forums are both volunteer run and funded by donations to the APSFA.

Website hosted by Dreamhost. Website created and maintained by Heidi P.

DISCLAIMER: APS Foundation of America, Inc. website is not intended to replace standard doctor-patient visits, physical examination, and medical testing. Information given to members is only an opinion. All information should be confirmed with your personal doctor. Always seek the advice of a trained physician in person before seeking any new treatment regarding your medical diagnosis or condition. Any information received from APS Foundation of America, Inc. website is not intended to diagnose, treat, or cure. This site is for informational purposes only. Please note that we will be listing all donor or purchaser's names on the Donor page of our foundation site. If you do not want your name listed, please contact us to opt out. If you think you may have a medical emergency, call your doctor or 911 immediately.

APS Foundation of America, Inc. will be building a database with your email, name and address information for future mailings. Your information will be kept confidential and not sold to any third parties. You may opt out at anytime by emailing us.

APSFA ©2005-2011 | APSFA Privacy Policy | APSFA Advertising Policy | 501(c)3 Public Charity EIN #203085295